Search

Your search keyword '"Uy, Geoffrey L."' showing total 153 results

Search Constraints

Start Over You searched for: Author "Uy, Geoffrey L." Remove constraint Author: "Uy, Geoffrey L." Search Limiters Academic (Peer-Reviewed) Journals Remove constraint Search Limiters: Academic (Peer-Reviewed) Journals
153 results on '"Uy, Geoffrey L."'

Search Results

1. Clinical evaluation of complete remission (CR) with partial hematologic recovery (CRh) in acute myeloid leukemia: a report of 7235 patients from seven cohorts

2. A randomized phase III study of standard versus high-dose cytarabine with or without vorinostat for AML

3. Sex-associated differences in frequencies and prognostic impact of recurrent genetic alterations in adult acute myeloid leukemia (Alliance, AMLCG)

5. Outcome prediction by the 2022 European LeukemiaNet genetic-risk classification for adults with acute myeloid leukemia: an Alliance study

6. Standardising acute myeloid leukaemia classification systems: a perspective from a panel of international experts

7. Immunosuppression and outcomes in adult patients with de novo acute myeloid leukemia with normal karyotypes

8. Distinct clonal identities of B-ALLs arising after lenolidomide therapy for multiple myeloma

9. The role of allogeneic transplant for adult Ph+ ALL in CR1 with complete molecular remission: a retrospective analysis

14. CPX-351 versus 7+3 cytarabine and daunorubicin chemotherapy in older adults with newly diagnosed high-risk or secondary acute myeloid leukaemia: 5-year results of a randomised, open-label, multicentre, phase 3 trial

16. Gene expression signature predicts relapse in adult patients with cytogenetically normal acute myeloid leukemia

17. Flotetuzumab as salvage immunotherapy for refractory acute myeloid leukemia

20. Gilteritinib as Post-Transplant Maintenance for AML With Internal Tandem Duplication Mutation of FLT3.

21. Identifying long-term survivors and those at higher or lower risk of relapse among patients with cytogenetically normal acute myeloid leukemia using a high-dimensional mixture cure model.

22. Reduced intensity conditioning for acute myeloid leukemia using melphalan- vs busulfan-based regimens: a CIBMTR report

23. Clinical and functional significance of circular RNAs in cytogenetically normal AML

24. Geriatric assessment among older adults receiving intensive therapy for acute myeloid leukemia: Report of CALGB 361006 (Alliance)

28. Allogeneic hematopoietic cell transplantation compared to chemotherapy consolidation in older acute myeloid leukemia (AML) patients 60–75 years in first complete remission (CR1): an alliance (A151509), SWOG, ECOG-ACRIN, and CIBMTR study

30. Complex karyotype in de novo acute myeloid leukemia: typical and atypical subtypes differ molecularly and clinically

31. Impact of a 40-Gene Targeted Panel Test on Physician Decision Making for Patients With Acute Myeloid Leukemia

32. Results of a Prospective Randomized, Open-Label, Noninferiority Study of Tbo-Filgrastim (Granix) versus Filgrastim (Neupogen) in Combination with Plerixafor for Autologous Stem Cell Mobilization in Patients with Multiple Myeloma and Non-Hodgkin Lymphoma

34. Mobilization of allogeneic peripheral blood stem cell donors with intravenous plerixafor mobilizes a unique graft

38. Hematopoietic Cell Transplantation Outcomes in Monosomal Karyotype Myeloid Malignancies

41. Genomic analysis of germ line and somatic variants in familial myelodysplasia/acute myeloid leukemia

44. Effect of Postremission Therapy before Reduced-Intensity Conditioning Allogeneic Transplantation for Acute Myeloid Leukemia in First Complete Remission

45. Protective Effect of Cytomegalovirus Reactivation on Relapse after Allogeneic Hematopoietic Cell Transplantation in Acute Myeloid Leukemia Patients Is Influenced by Conditioning Regimen

47. Intergroup LEAP trial (S1612): A randomized phase 2/3 platform trial to test novel therapeutics in medically less fit older adults with acute myeloid leukemia

48. Outcomes of Older Adults With AML Treated in Community Versus Academic Centers: An Analysis of Alliance Trials.

49. A randomized phase II/III study of 'novel therapeutics' versus azacitidine in newly diagnosed patients with acute myeloid leukemia (AML), high-risk myelodysplastic syndrome (MDS), or chronic myelomonocytic leukemia (CMML), age 60 or older: a report of the comparison of azacitidine and nivolumab to azacitidine: SWOG S1612

Catalog

Books, media, physical & digital resources